Objective To explore clinical effect and safety of amiodarone combined with bisoprolol in patients with congestive heart failure and ventricular arrhythmia. Methods Selected 100 cases with congestive heart failure and ventricular arrhythmia in our hospital from January 2011 to April 2017 as research objectives and divided them into two groups randomly with 50 cases in each group. Provided amiodarone to control group and provided amiodarone combined with bisoprolol to observation group. Compared two groups' arrhythmia and cardiac function, heart rate, ejection fraction, QT time (QTc) corrected for heart rate before and after treatment as well as adverse events. Results Observation group's effective rate of arrhythmia treatment and the effective rate of cardiac function were 94.00％, 96.00％, those were significant higher than control group's 70.00％, 78.00％ (P<0.05). Two groups' heart rate and ejection fraction score after 3 month treatment were significant higher than those before treatment (P<0.05), and observation group's improvement was more significant (P<0.05). Observation group's QTc was significantly prolonged after 3 months of treatment (P<0.05), but control group's QTc did not change significantly. There was no significant difference in the incidence of adverse reactions between the two groups. Results Amiodarone combined with bisoprolol has significant clinical effect on patients with congestive heart failure and ventricular arrhythmia. It is safe and worthy to be promoted clinically.

OBJECTIVETo investigate whether bortezomib can enhance the sensitivity of human prostate cancer (PCa) cells to natural killer (NK) cell-mediated cytotoxicity, and whether it produces the same effect on different PCa cell lines.

METHODSWe treated androgen-dependent PCa LNCaP cells and androgen-independent PCa DU145 cells with bortezomib at the concentrations of 0, 5, 10, 15, 20 and 25 nmol/L for 24, 48 and 72 hours, and then detected the proliferation and apoptosis of the tumor cells by CCK-8 and Annexin V/PI, respectively.

RESULTSThe proliferation rates of the DU145 cells treated with 15, 20 and 25 nmol/L bortezomib were (82.79 +/-2.04)%, (73.59+/- 2.95)% and (74.16+/- 6. 16)% at 48 hours and (71.24+/- 5.30)%, (51.20+/- 2.91)% and (38.02+/- 2.67)% at 72 hours, and those of the LNCaP cells were (77.04+/- 7.74)% , (42.61 +/- 6.62)% and (23.85 +/-6.04)% at 48 hours and (36.45 +/-7.02)%, (14.94 +/-5.76)% and (11.65 +/-5. 87)% at 72 hours, both significantly inhibited as compared with the control group (P <0.05). At 24 hours, the apoptosis rates of the DU145 cells treated with 15, 20 and 25 nmol/L bortezomib were (14.41 +/- 1.32)% , (16.13 +/- 1.55)% and (14.48 +/- 1.42)% , and those of the LNCaP cells treated with 20 and 25 nmol/L bortezomib were (12.77 +/- 1.28)% and (14. 84 +/- 1.65)% , significantly higher than those of the control group (P <0.05) , and the DU145 cells showed an even higher sensitivity to bortezomib than the LNCaP cells. Bortezomib failed to sensitize these two cell lines to NK cell-mediated cytotoxicity in short-term assay, while long-term assay manifested that the apoptosis rates of DU145 and LNCaP cells after treated with 20 nmol/L bortezomib + NK cells were (41.83 +/- 5.06)% and (30.31 +/- 3.62)% , respectively, significantly higher

CONCLUSIONBortezomib enhances the sensitivity of than those after treated with either bortezomib or NK cells alone (P <0.05). PCa cells to NK cell-mediated cytotoxicity and adds to the effect of current cancer therapies, and it is more efficacious for androgen-independent prostate cancer.

Apoptosis ; drug effects ; Boronic Acids ; pharmacology ; Bortezomib ; Cell Line, Tumor ; Cytotoxicity, Immunologic ; drug effects ; Humans ; Killer Cells, Natural ; drug effects ; Male ; Prostatic Neoplasms ; pathology ; Pyrazines ; pharmacology

Objective To investigate the relationship between ambulatory arterial stiffness index (AASI) derived from blood pressure monitoring and early signs of renal damage in patients with primary hypertension． Methods 74 primary hypertensive outpatients were divided into two groups according to their AASI values: normal AASI group (AASI≤0.51, n=40) and high AASI group (AASI>0.51, n=32). The urinary micro-albumin, glomerular filtration rates (GFR) were measured and compared. The relationship between AASI and micro-albumin, GFR were tested with Pearson correlation and multiple Logistic regression. Results Compared with those in the normal AASI group, the patients in high AASI group showed a higher level of urinary microalbumin (P<0.05) and a reduction in GFR (P<0.01). AASI was positively correlated with urinary microalbumin （r=0.32, P<0.001）, and negatively correlated with GFR （r=0.44, P<0.001）. After adjusting the potentially confounding variables, the odd ratio (OR) of AASI to renal damage was 2.18 （P=0.008，95%CI：1.76～4.34）. Conclusion The increase of AASI is associated with early signs of renal damage in patients with primary hypertension.

Objective To study the efficacy and security of solifenacin in prevention of cystospasm after radical prostatectomy. Methods The clinical data of 93 localized prostate cancer patients who had underwent laparoscopic radical prostatectomy were retrospectively analyzed. The patients were divided into solifenacin group (52 cases) and control group (41 cases) based on the condition of taking solifenacin after operation. The day and night frequency and duration of cystospasm from the first day to the third day after operation, incidence of urine extravasation, duration of bloody urine, time of pelvic cavity drainage and ureter retention, untoward reaction (dry mouth, headache and abdominal distention) was compared between two groups. Results The day and night frequency and duration of cystospasm at second day and third day after operation in solifenacin group were significantly lower than those in control group. Day frequency of cystospasm: (1.54 ± 0.42) times vs. (3.35 ± 0.43) times and (1.38 ± 0.58) times vs. (2.86 ± 0.66) times, night frequency of cystospasm:(1.66 ± 0.63) times vs. (3.58 ± 0.72) times and (1.47 ± 0.33) times vs. (3.27 ± 0.68) times, duration of cystospasm:(0.18 ± 0.11) h vs. (0.33 ± 0.18) h and (0.21 ± 0.09) h vs. (0.29 ± 0.21) h, and the incidence of urine extravasation at the third day after operation in solifenacin group was significantly lower than that in control group: 1.92% (1/52) vs. 17.07% (7/41), and there were statistical differences (P<0.05). The duration of bloody urine, time of pelvic cavity drainage and ureter retention after operation in solifenacin group were significantly shorter than those in control group:(30.2 ± 5.6) h vs. (48.3 ± 4.7) h, (50.6 ± 5.9) h vs. (70.3 ± 6.2) h and (7.6 ± 1.4) d vs. (10.4 ± 0.9) d, and there were statistical differences (P<0.05). There was no statistical difference in untoward reaction between 2 groups (P>0.05). Conclusions Solifenacin can reduce the frequency of cystospasm and shorten the duration of cystospasm effectively after radical prostatectomy. It has a positive effect on reducing the incidence of urinary extravasation and shorting the extubation time. It is helpful to improve the quality of life and the recovery of the patients.

Objective Toinvestigatethecorrelationsofthelevelsofplasmasolublereceptorfor advanced glycation end product (sRAGE )with the National Institutes of Health Stroke Scale (NIHSS ), grade of white matter lesions,and risk factors for cerebral vascular disease in patients with acute cerebral infarction.Methods Atotalof120patientswithacutecerebralinfarctionwereenrolledretrospectively. They all underwent head MRI. The plasma sRAGE levels of the acute cerebral infarction group and 120 healthy subjects were detected with enzyme-linked immunosorbent assay (ELISA)and were compared. According to the interquartile range (P25 =540 ng/L,P50 =1030 ng/L,P75 =1400 ng/L ),the plasma sRAGE levels were divided into 4 quartiles (Q1 to Q4). Q1:sRAGE<540 ng/L (n=29),Q2:540 ng/L≤sRAGE≤1030 ng/L (n=31),Q3:1030 ng/L < sRAGE≤1400 ng/L (n =30),and Q4:sRAGE >1400 ng/L (n =30 ). The plasma sRAGE levels in the acute cerebral infarction group and the healthy control group were compared using the Wilcoxon rank sum test. Multiple linear regression analysis was used to analyze the correlations of the sRAGE levels with NIHSS scores,grade of cerebral white matter lesions,and cerebrovascular risk factors. Results (1 )The median level of plasma sRAGE was 870 (540.0,1403. 8)ng/L in the acute cerebral infarction group,which was lower than 1032 (727. 5,1721. 5) ng/L in the healthy control group. There was significant difference (P<0. 05). (2)Single factor analysis showed that the smoking rate,NIHSS scores,the types of deep white matter hyperintensity (DWMH),and the estimated glomerular filtration rate(eGFR)among Q1,Q2,Q3 and Q4 quartiles were significant different (all P<0.05). The smoking rate,ratio of patients with high NIHSS score,incidence of severe DWMH and percentage of the patients with normal eGFR in Q1 (n=29)were 62. 1%(n=18), 44. 8%(n=13),55.2%(n=16)and 51. 7%(n=15),respectively,and they had a higher trend than other quartiles. (3)Multiple linear regression analysis showed that the smoking,NIHSS score,eGFR,and severity of DWMH were the influence factors of the levels of plasma sRAGE in patients with acute cerebral infarction.Thereweresignificantdifferences(allP<0.05).Conclusion Theexpressionlevelsofthe plasma sRAGE in patients with acute cerebral infarction group is significantly lower than those in the healthy subjects,and smoking,neurological defect,eGFR,and severity of DWMH are associated the low level of sRAGE. sRAGE may be used as a reference index for predicting the conditions of acute cerebral infarction.

Objective To explore the pre-requisite "highlight" of information system in a new outpatient building and its significance on outpatient information construction.Methods The importance of new outpatient information system for improving the treatment of the environment and optimizing the outpatient treatment processes were analyzed from information dissemination system,self-service system and intelligent queuing system.Results The systemic design plan and actual role of the three systems were given by combining actual situation of the new outpatient building construction.Conclusion Having greatly improving for the outpatient information construction and the new outpatient building will have a positive impact on hospital management model,medical model and informationation construction.

BACKGROUND: The curative effect is satisfactory for adult patients with spasticity of lower limbs treated with selective posterior rhizotomy and peripheral nerve micro diminution. But how to improve the strength of relevant muscle is the key factor to accelerate recovery of motor function during rehabilitation training.OBJECTIVE: To observe the effect of muscle stimulating instrument on the recovery of muscle strength and the improvement of motor function of adults with spasticity of lower limbs during rehabilitation training.DESIGN: Case analysis.SETTING: Department of Neurosurgery, China-Japan Friendship Hospital of Beijing Ministry of Public Health.PARTICIPANTS: Totally 49 adults with spasticity of lower limbs were selected from Department of Neurosurgery, China-Japan Friendship Hospital of Beijing Ministry of Public Health from January 2000 to May 2002.There were 37 males and 12 females aged from 19-48 years. Totally 21patients treated with muscle stimulating instrument were determined as treatment group and other 28 patients were determined as control group during rehabilitation training.METHODS: One day after operation, conventional rehabilitation training was performed on patients in the treatment group and the control group.Patients in the treatment group were also treated with muscle stimulating instrument three times a day with each for 30 minutes for totally 7 days as a course. There was a three-day interval between treating courses and the rehabilitative time lasted for 6 months. Before rehabilitation training, indexes of patients in the two groups, such as ankle extension, knee flexion and muscle strength of thigh adductor, were recorded and the improvement of muscle strength after 3 and 6 months was followed up.MAIN OUTCOME MEASURES: Average strength of relevant muscle before and after 3-month and 6-month rehabilitation training.RESULTS:Totally 49 patients entered the final analysis.①After 3-month and 6-month treatment, indexes of ankle extension, knee flexion and muscle strength of thigh adductor were increased at various degrees.②During 3-month and 6-month treatment,indexes of ankle extension,knee flexion and muscle strength of thigh adductor in the treatment group were obviously higher than those in the control group [3-month treatment:(4.2±0.8), (3.7±0.7) degrees; (4.3±0.7), (3.8±0.7) degrees; (4.0±0.7), (3.5±0.5)degrees; 6-month treatment: (4.5±0.6), (3.9±0.7) degrees; (4.6±0.7), (4.0±0.5)degrees; (4.4±0.7), (4.0±0.6) degrees, (P ＜ 0.05 or P ＜ 0.01)].CONCLUSION: The combination of rehabilitation training and muscle stimulating instrument can accelerate the recovery of muscle strength and motor function in adults with spasticity of lower limbs after microsurgical treatment.

AIM:To explore the effect of recombined sICAM-1 on the adhesion of leukocyte to pulmonary microvascular endothelial cell. METHODS:Primary cultured rat pulmonary microvascular endothelial cells were used in this experiment. Leukocyte was labeled with 99　Tm-HMPAO.The effects of different dose of sICAM-1, CA7 and dimeric form of sICAM-1 (sICAM-1*CA7)were tested separately in cell adhesion .RESULTS:sICAM-1 and CA7 could not inhibit cell adhesion even at the concentration of 100 mg/L,while sICAM-1*CA7 at concentrations of 20 mg/L and 40 mg/L could inhibit 42% and 50% of cell adhesion respectively (P＜0.05). CONCLUSION:sICAM-1 has poor inhibitory effect on cell adhesion, probably due to monomeric form.